---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-301829"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:20:39.558310+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences dosed first patient in SURF201 for TYRA-200; TYRA-300 Part A clears dose cohorts; plans ACH IND H2 2024

## Summary
- First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.
- SURF301 Part A dose escalation cleared multiple cohorts above anticipated dose for Phase 2 achondroplasia study.
- Expansion cohorts in SURF301 Part B at dose levels anticipated for oncology evaluation.
- Tyra plans to submit initial SURF301 Phase 1 results for a scientific congress in 2024.
- Company plans to submit IND for TYRA-300 in pediatric achondroplasia in H2 2024, starting with ages 5-12.

## SEC filing metadata
- accession: 0001193125-23-301829
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/0001193125-23-301829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/d489661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-301829
- JSON: https://secwatch.observer/filing/0001193125-23-301829.json
- Plain text: https://secwatch.observer/filing/0001193125-23-301829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.